IPSOS: Results from a Phase 3 study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
This presentation reports the results from IPSOS (NCT03191786), a global, open-label, randomized, phase III study of atezolizumab versus single-agent chemotherapy in patients ineligible for first-line platinum-doublet chemotherapy. The presented data include the primary endpoint of overall survival, secondary endpoints such as OS rates, ORR, PFS, and DOR, and an assessment of safety and quality of life measures.